Richard White
@richardwhite321
Followers
5K
Following
16K
Media
84
Statuses
4K
B-sky: https://t.co/vEo2SZUZEh Prof @LSHTM. Science for tuberculosis policy & practice. Author of https://t.co/XUP441dTIv. Amateur choir member. View own
London, England
Joined January 2009
Loved sharing the ups and downs of the last 20 years at LSHTM yesterday. Thanks to everybody who came, for making it so special! @tb_mac @LSHTM_TB @cmmid_lshtm #TB
1
10
36
Huge thanks to all authors: . @GavinChurchyard.@kc_horton.@agartland.@mbehr_mcgill.@ra_clark18.Frank Cobelens.Joel D Ernst.@hanifesmail_tb.@agbasteiro.Sri Rezeki Hadinegoro.@WillemAHanekom.Mark Hatherill.Phil Hill.Rudzani Muloiwa.Puck T Pelzer.@LeleRangaka.Helen Rees.Lew Schrager.
1
0
1
5/5 If asymptomatic tuberculosis disease can be included, it could lead to cheaper and more rapid tuberculosis vaccine development.
1
0
0
4/5 Crucially, research studies are needed to generate the evidence needed to evaluate if asymptomatic tuberculosis disease could be included in the primary endpoint of tuberculosis vaccine licensure trials.
1
0
0
3/5 There are risks, which include missing a useful vaccine against symptomatic tuberculosis if the vaccine does not have efficacy against asymptomatic tuberculosis, and potential overtreatment of asymptomatic tuberculosis, which could self-cure.
1
0
0
2/5 Including asymptomatic tuberculosis disease in the primary endpoint might increase the number of endpoints, leading to smaller or shorter vaccine trials.
1
0
0
Key messages. 1/5 Tuberculosis vaccine licensure trials using symptomatic tuberculosis disease as the primary endpoint are large, long, and expensive.
1
0
0
Could TB vaccine trials be faster, smaller, cheaper?. Our new Lancet Respir Med piece argues that including asymptomatic bacteriologically confirmed TB disease in the primary endpoint could be transformative—if the right evidence is generated.
1
4
7
RT @JMDBarroso: This week's Global Summit secured a record of number of pledges and welcomed new donors to accelerate @Gavi’s impact from 2….
0
4
0
RT @juliocroda: 🦠✨ New Personal View in @TheLancetInfDis: Should people deprived of liberty (PDL) be protected from research or through res….
0
2
0
Tomorrow :).
Can you believe it’s been 25 years!? . Join us on 20 June 2025 at 4pm UK time to celebrate 25 years of the Introduction to Infectious Disease Modelling course by @LSHTM and @UKHSA. Hear @neil_ferguson on What modelling might be like in 25 years, & students' modelling adventures
0
0
0
Can you believe it’s been 25 years!? . Join us on 20 June 2025 at 4pm UK time to celebrate 25 years of the Introduction to Infectious Disease Modelling course by @LSHTM and @UKHSA. Hear @neil_ferguson on What modelling might be like in 25 years, & students' modelling adventures
1
5
7
RT @CFMcQuaid: TB & climate change: @WHO report out now, building on an analytical framework we developed to explore the intersections and….
0
4
0
Today :).
@LSHTM_TB May Seminar Hyrid free & open to all.📅 27 May .⏰12.45 BST ."Defining efficacy endpoints for late phase tuberculosis treatment non-inferiority trials" @DanielJGrint @tomayates @richardwhite321 @TogunToyin.
0
0
0
Are you interested in #TB and have experience in #modelling infectious diseases? . Come join us in the fun, supportive, and world-leading TB Modelling Group at @LSHTM ! . We have a 1 year Research Fellow position (with possible extension) . Closing date of 30 May 2025 👉.
0
11
16
There was a call to collate data on trial expenditure to explore if vaccines could be developed more efficiently. That’s a wrap! . Presentations will be available: thanks to Angela Hwang's excellent work. Feel free to get in touch.
0
0
0
There was also discussion about the high cost of vaccine trials. For-profit contract research organisations were mentioned as a potential factor, but there is a lack of empirical data.
1
0
0